Abstract
Temozolomide (TMZ) is a prodrug for an alkylating agent used for the treatment of malignant brain tumors. A positron emitting version, [(11)C]TMZ, has been utilized to help elucidate the mechanism and biodistribution of TMZ. Challenges in [(11)C]TMZ synthesis and reformulation make it difficult for routine production. A highly reproducible one-pot radiosynthesis of [(11)C]TMZ with a radiochemical yield of 17 ± 5% and ≥97% radiochemical purity is reported.
MeSH terms
-
Antineoplastic Agents, Alkylating / chemical synthesis*
-
Antineoplastic Agents, Alkylating / chemistry
-
Antineoplastic Agents, Alkylating / pharmacology
-
Brain Neoplasms / drug therapy*
-
Carbon Radioisotopes / chemistry
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / chemical synthesis
-
Dacarbazine / chemistry
-
Dacarbazine / pharmacology
-
Molecular Structure
-
Radiopharmaceuticals / chemical synthesis*
-
Radiopharmaceuticals / chemistry
-
Radiopharmaceuticals / pharmacology
-
Temozolomide
-
Tissue Distribution
Substances
-
Antineoplastic Agents, Alkylating
-
Carbon Radioisotopes
-
Radiopharmaceuticals
-
Dacarbazine
-
Temozolomide